This is supported by a previous article suggesting that KRAS and BRAF mutations with consequent activation of MEK1/2-ERK1/2 signaling increase the risk of lung metastasis in colorectal cancer patients [51]. This evidence concerns the gene KRAS and colorectal cancer.